<DOC>
	<DOCNO>NCT00732407</DOCNO>
	<brief_summary>Aliskiren novel renin inhibitor approve treatment hypertension . The effect aliskiren arterial stiffness , inflammation oxidative stress fully investigate yet.The aim study investigate effect aliskiren arterial stiffness , platelet function inflammation compare losatan patient diabetes mellitus . We hypothesize aliskiren beneficial effect arterial stiffness platelet function patient diabetes mellitus .</brief_summary>
	<brief_title>Aliskiren 's Effect Arterial Stiffness Platelet Function Patients With Diabetes Mellitus ( DM )</brief_title>
	<detailed_description>Background : Patients diabetes mellitus ( DM ) increase risk atherothrombotic event . Platelets play important role cardiovascular disease pathogenesis atherosclerosis development acute thrombotic event . Their importance coronary heart disease indirectly confirm benefit antiplatelet agent disorder . Platelet adhesion , aggregation activation abnormal patient DM . Several factor find associated abnormality platelet signal patient DM , include increase level reactive oxygen specie , alter calcium mobilization increase protein tyrosine phosphorylation . Arterial stiffness , assess noninvasively measure aortic pulse wave velocity ( PWV ) , consider powerful independent risk factor early mortality . Increased arterial stiffness may lead early pulse wave reflection cause increase systolic blood pressure decrease diastolic blood pressure . This turn , increase myocardial oxygen demand , reduce ejection fraction increase leave ventricular work load . PWV probably represent integrated index vascular structure function , influence many factor include age , blood pressure , lipid profile glucose level . For level systolic blood pressure , aortic PWV find increase diabetic patient compare nondiabetic patient . Aliskiren first direct renin inhibitor introduce treatment hypertension . Aliskiren bind active site renin , inhibit activation renin- angiotensin- aldosteron ( RAAS ) system rate limit step . Aliskiren inhibit conversion angiotensinogen angiotensin I ( AI ) . This direct inhibition may efficient indirect blockade ACE inhibitor ARBs . Except BP lower effect aliskiren find increase renal blood flow high degree find angiotensin convert enzime ( ACE ) inhibitor angiotensin receptor blocker ( ARBs ) . Moreover- block active site prorenin/renin ( ( pro ) renin ) receptor reduce local angiotensin II ( AII ) generation . Renin inhibitor , like ACE inhibitor ARBs , increase concentration renin activates ( pro ) renin receptor . Renin receptor find kidney , blood vessel heart . Binding renin receptor increase catalytic effect probably activate potentially pathogenic , mitogen activate protein kinase pathway . It tissue damage effect increase frofibrotic pathway expression molecules TGF- beta . In recent study aliskiren find bind renin prorenin receptor increase stability , rise probably cause AII generation although allows detection prorenin renin . Aliskiren increase amount circulate immunoreactive renin decrease PRA . Uresin Y et al compare efficacy safety aliskiren ramipril patient diabetes hypertension . Aliskiren find effective lower systolic blood pressure ( SBP ) ramipril , show inferiority reduce diastolic blood pressure ( DBP ) . When used combination ramipril , aliskiren show significant additional reduction SBP DBP . In study , plasma renin concentration ( PRC ) significantly increase monotherapy combine , PRC increase great level sum effect alone . The reactive rise PRC associate concomitant rise plasma renin activity ( PRA ) ramipril group , effect suppress combined aliskiren . Other recent study find similar result compare efficacy safety aliskiren ramipril add treatment valsartan . Safety aliskiren also evaluate elderly patient ( 65 ) find effectively reduce blood pressure well tolerate subgroup patient . Inhibition RAAS diabetic patient know result several beneficial effect , independent BP lower effect ; Reduction albumin excretion , prevention progression renal disease possibly cardio-protective effect . Valsartan also find reduce PWV , hence arterial stiffness , diabetic patient independently BP lower effect . Several effect already evaluate use aliskiren , example : Nussberger J al evaluate effect aliskiren atherosclerosis plaque stabilization mouse , compare atenolol , amlodipine irbesartan . They find although similar blood pressure lower effect , aliskiren irbesartan beneficial effect plaque phenotype ( include smooth muscle cell content , fibrous cap , lipid core , medial degeneration macrophage content ) whereas amlodipine atenolol . Lu H et al . evaluated effect aliskiren atherosclerosis LDL receptor deficient mouse . They find significant reduction atherosclerotic plaque size aortic root arch aliskiren treat mouse . Aliskiren find reduce BP , prevent albuminuria suppress renal gene expression ( pro ) renin receptor model hypertensive diabetic renal damage rat . It also exhibit potential inhibit prorenin . When use combination aliskiren losartan patient DM , aliskiren reveal reno-protective effect independent BP lower effect . The effect aliskiren arterial stiffness yet evaluate . Several study evaluate effect RAAS system inhibitor platelet function hemostasis , example perindopril find anti-platelet profibrinolytic effect telmisartan find anticoagulant effect . Perindopril also find reduce platelet aggregation adrenaline induce platelet aggregation . The effect aliskiren platelet activity clear . In vitro study biomarkers platelet activity alter aliskiren ( except moderate increase antithrombin-III activity ) . At high dos ( exceed therapeutic range ) diverge effect - platelet activate antiplatelet effect Purpose : The purpose study evaluate effect aliskiren , inhibit rate limit step RAAS system , arterial stiffness , inflammation platelet function patient DM . Methods : Study design : The study prospective , cross , randomize trial . All patient fulfil inclusion exclusion criterion , short screening period , treat aliskiren losartan . After washout period 2 week cross make two group . Aliskiren give preliminary dosage 150 mg per day , follow two week dosage increase 300 mg per day . Losartan give preliminary dosage 50 mg per day two week follow dosage increase 100 mg per day . Two week initiation treatment potassium creatinin level assess . The follow conduct Research Development unit Assaf Harofeh Medical Center 0 , 3 6 month wash period . On visit patient BP assess 24 ambulatory BP monitoring . Blood drawn ( 10 cc ) Hemoglobin level , electrolyte , renal liver function , total cholesterol , high density lipoprotein-cholesterol ( HDL- cholesterol ) , triglyceride ( TG ) , oxidize low density lipoprotein ( ox-LDL ) hs- CRP . LDL-cholesterol calculate . PRA measure radioimmunoassay generate AI , PRC plasma aldosterone measure immunochemiluminescence . In addition NO isoprostane measure index oxidative stress . Platelet function arterial stiffness assess . The patient ' medication regimen change throughout study period . Platelet Function Tests Cone-and-Platelet Analyzer 200 µL citrate blood place polystyrene well subject shear rate 1300 sec-1 use rotate conical disk 2 minute . The well washed stain May-Gruenwald stain . Platelet adhesion evaluate percentage total area cover platelet designate surface coverage ( % ) aggregation mean size surface-bound aggregate designate average size ( µ ` m2 ) use image analysis system ( Galai ) . Aspirin Response Assay 3.6µl Arachidonic Acid 0.2 ml blood add micro tube ( 2ml ) , ( final Arachidonic Acid concentration 0.275 mM ) . The tube rotate tube mixer 10 rpm 1 minute . 130 µl place well test cone platelet analyzer . Clopidogrel Response Assay 5 µl ADP 0.2 ml blood add micro tube ( 2 ml ) ( final ADP concentration 1.25 µM ) . The tube rotate tube mixer 10 rpm 1 minute . 130 µl place well test cone platelet analyzer . ( Varon D et al 1997 ) Arterial stiffness Assessment arterial stiffness perform noninvasive technique use commercially available SphygmoCor System ( AtCor Medical LTD , Australia ) . All measurement perform patient recumbent position room temperature 25۫ C , 06:30 08:30 A.M. overnight fasti ( 8-10 hour ) short period rest . Peripheral pressure waveform record radial artery wrist , use applanation tonometry high fidelity micromanometer . When sequential waveform record , validate 16-18 generalized transfer function apply generate corresponding central pressure waveform . The integral system software use calculate average radial artery waveform derive corresponding central aortic pressure waveform use previously validate generalize transfer function . From data index arterial stiffness obtain . The augmentation central arterial pressure difference first second systolic peak central pressure waveform , central augmentation index ( AIx ) augmentation express percentage pulse pressure . This technology easy use , non-invasive , simple , rapid ( 15 minute per test ) repeatable .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Losartan</mesh_term>
	<criteria>The study include 40 patient age 18 year old DM , define patient fast plasma glucose 126 mg/dL symptom DM random blood glucose concentration 200 mg/dL , patient treat oral hypoglycemics insulin . In addition , prior enrollment study patient ' BP assess 24 hour ambulatory BP monitoring . All patient treat ACE inhibitor , aspirin statin least one month prior enrollment study . Patients ' medication regimen alter study period . Patients sign write informed consent inclusion study . Patients exclude study systolic BP bellow 110 mmHg 150 mmHg mmHg . Major exclusion criterion : acute coronary syndrome 6 month previous study , renal failure creatinin level 1.5 mg/dL , hyperkalemia ( K &gt; 5 mg/dL ) , hematologic solid malignancy , pregnancy platelet count 100,000 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>aliskiren</keyword>
	<keyword>arteial stiffness</keyword>
	<keyword>platelet function</keyword>
	<keyword>diabetes mellitus</keyword>
</DOC>